Skip to main content
Top
Published in: BMC Ophthalmology 1/2014

Open Access 01-12-2014 | Research article

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in the aqueous humour of patients with primary angle closure glaucoma - a quantitative study

Authors: Angeline DC Nga, Soon-Lek Yap, Amir Samsudin, Puteri S Abdul-Rahman, Onn H Hashim, Zahari Mimiwati

Published in: BMC Ophthalmology | Issue 1/2014

Login to get access

Abstract

Background

Altered levels of specific matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in the aqueous humour of primary open-angle glaucoma (POAG) eyes have been described. In this study, levels of specific MMPs and TIMPs in the aqueous humour of primary angle-closure glaucoma (PACG) eyes were measured and compared with those of POAG as well as non-glaucoma control eyes.

Methods

Aqueous humour from 16 PACG, 28 POAG and 27 control eyes were sampled during intraocular surgery. Levels of total protein, MMP-2, MMP-3, TIMP-1 and TIMP-2 were quantified by protein assay and enzyme immunoassay.

Results

Total protein levels were significantly higher in PACG (0.426 ± 0.126 mg/ml, p = 0.043) and POAG (0.578 ± 0.360 mg/ml, p = 0.007) compared to controls (0.292 ± 0.192 mg/ml). The difference between PACG and POAG was not significant (p = 0.158). MMP-2 was significantly higher in PACG (p = 0.032) and POAG (p < 0.001) compared to controls. The difference between PACG and POAG was also not significant (p = 0.133). MMP-3 was significantly higher in POAG compared to controls (p = 0.002) and PACG (p = 0.029). The difference between PACG and controls was not significant (p = 0.962). TIMP-1 was significantly higher in PACG (p = 0.049) and POAG (p = 0.010) compared to controls. The difference between PACG and POAG was also not significant (p = 0.961). TIMP-2 was significantly higher in POAG (p = 0.004) compared to controls. The difference between PACG and either controls or POAG was not significant (p > 0.05). Although not statistically significant (p > 0.05), the MMP-2/TIMP-2 ratio was highest in PACG (2.83 ± 7.40), followed by POAG (1.38 ± 1.55) and controls (1.34 ± 3.05). Similarly, the MMP-2/TIMP-1 ratio was highest in PACG (1.50 ± 1.69), followed by POAG (1.40 ± 0.77) and controls (1.15 ± 0.92). The MMP-2 + MMP-3/TIMP-1 + TIMP-2 ratio was higher in PACG (0.83 ± 0.80) and POAG (0.82 ± 0.53) compared to controls (0.70 ± 0.63). In both POAG and PACG, there were no significant differences in the levels of total protein, MMP-2, MMP-3, TIMP-1 and TIMP-2 between patients on prostaglandin analogues and those not.

Conclusion

We found altered levels of MMPs and TIMPs as well as imbalance of MMP:TIMP ratios in the aqueous humour of PACG eyes that were different from POAG and non-glaucoma control eyes.
Appendix
Available only for authorised users
Literature
2.
go back to reference De Groef L, Van Hove I, Dekeyster E, Stalmans I, Moons L: MMPs in the trabecular meshwork: promising targets for future glaucoma therapies?. Invest Ophthalmol Vis Sci. 2013, 54: 7756-7763. 10.1167/iovs.13-13088.CrossRefPubMed De Groef L, Van Hove I, Dekeyster E, Stalmans I, Moons L: MMPs in the trabecular meshwork: promising targets for future glaucoma therapies?. Invest Ophthalmol Vis Sci. 2013, 54: 7756-7763. 10.1167/iovs.13-13088.CrossRefPubMed
3.
go back to reference Sivak JM, Fini ME: MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res. 2002, 21 (1): 1-14. 10.1016/S1350-9462(01)00015-5.CrossRefPubMed Sivak JM, Fini ME: MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res. 2002, 21 (1): 1-14. 10.1016/S1350-9462(01)00015-5.CrossRefPubMed
4.
go back to reference Dushku N, John MK, Schultz GS, Reid TW: Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Arch Ophthalmol. 2001, 119 (5): 695-706. 10.1001/archopht.119.5.695.CrossRefPubMed Dushku N, John MK, Schultz GS, Reid TW: Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Arch Ophthalmol. 2001, 119 (5): 695-706. 10.1001/archopht.119.5.695.CrossRefPubMed
5.
go back to reference Das A, McLamore A, Song W, McGuire PG: Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol. 1999, 117 (4): 498-503. 10.1001/archopht.117.4.498.CrossRefPubMed Das A, McLamore A, Song W, McGuire PG: Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol. 1999, 117 (4): 498-503. 10.1001/archopht.117.4.498.CrossRefPubMed
6.
go back to reference Plantner JJ, Jiang C, Smine A: Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. Exp Eye Res. 1998, 67 (6): 637-645. 10.1006/exer.1998.0552.CrossRefPubMed Plantner JJ, Jiang C, Smine A: Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. Exp Eye Res. 1998, 67 (6): 637-645. 10.1006/exer.1998.0552.CrossRefPubMed
7.
go back to reference Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, Konstas AGP, Naumann GOH: Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/ glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003, 44 (3): 1117-1125. 10.1167/iovs.02-0365.CrossRefPubMed Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, Konstas AGP, Naumann GOH: Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/ glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003, 44 (3): 1117-1125. 10.1167/iovs.02-0365.CrossRefPubMed
8.
go back to reference Maatta M, Tervahartiala T, Vesti E, Airaksinen J, Sorsa T: Levels and activation of matrix metalloproteinases in aqueous humor are elevated in uveitis-related secondary glaucoma. J Glaucoma. 2006, 15 (3): 229-237. 10.1097/01.ijg.0000212229.57922.72.CrossRefPubMed Maatta M, Tervahartiala T, Vesti E, Airaksinen J, Sorsa T: Levels and activation of matrix metalloproteinases in aqueous humor are elevated in uveitis-related secondary glaucoma. J Glaucoma. 2006, 15 (3): 229-237. 10.1097/01.ijg.0000212229.57922.72.CrossRefPubMed
9.
go back to reference Ronkko S, Rekonen P, Kaarniranta K, Puustjärvi T, Teräsvirta M, Uusitalo H: Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma. Graefes Arch Clin Exp Ophthalmol. 2007, 245 (5): 697-704. 10.1007/s00417-006-0440-1.CrossRefPubMed Ronkko S, Rekonen P, Kaarniranta K, Puustjärvi T, Teräsvirta M, Uusitalo H: Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma. Graefes Arch Clin Exp Ophthalmol. 2007, 245 (5): 697-704. 10.1007/s00417-006-0440-1.CrossRefPubMed
10.
go back to reference Fountoulakis N, Labiris G, Aristeidou A, Katsanos A, Tentes I, Kortsaris A, Kozobolis VP: Tissue inhibitor of metalloproteinase 4 in aqueous humor of patients with primary open angle glaucoma, pseudoexfoliation syndrome and pseudoexfoliative glaucoma and its role in proteolysis imbalance. BMC Ophthalmol. 2013, 13: 69-75. 10.1186/1471-2415-13-69.CrossRefPubMedPubMedCentral Fountoulakis N, Labiris G, Aristeidou A, Katsanos A, Tentes I, Kortsaris A, Kozobolis VP: Tissue inhibitor of metalloproteinase 4 in aqueous humor of patients with primary open angle glaucoma, pseudoexfoliation syndrome and pseudoexfoliative glaucoma and its role in proteolysis imbalance. BMC Ophthalmol. 2013, 13: 69-75. 10.1186/1471-2415-13-69.CrossRefPubMedPubMedCentral
11.
go back to reference Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD: Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997, 38 (13): 2772-2780.PubMed Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD: Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997, 38 (13): 2772-2780.PubMed
12.
go back to reference Toris CB, Gulati V: The biology, pathology and therapeutic use of prostaglandins in the eye. Clin Lipidol. 2011, 6 (5): 577-591. 10.2217/clp.11.42.CrossRef Toris CB, Gulati V: The biology, pathology and therapeutic use of prostaglandins in the eye. Clin Lipidol. 2011, 6 (5): 577-591. 10.2217/clp.11.42.CrossRef
13.
go back to reference Foster PJ, Buhrmann R, Quigley HA, Johnson GJ: The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002, 86: 238-242. 10.1136/bjo.86.2.238.CrossRefPubMedPubMedCentral Foster PJ, Buhrmann R, Quigley HA, Johnson GJ: The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002, 86: 238-242. 10.1136/bjo.86.2.238.CrossRefPubMedPubMedCentral
14.
go back to reference He M, Lu Y, Liu X, Ye T, Foster PJ: Histologic changes of the iris in the development of angle closure in Chinese eyes. J Glaucoma. 2008, 17 (5): 386-392. 10.1097/IJG.0b013e31815c5f69.CrossRefPubMed He M, Lu Y, Liu X, Ye T, Foster PJ: Histologic changes of the iris in the development of angle closure in Chinese eyes. J Glaucoma. 2008, 17 (5): 386-392. 10.1097/IJG.0b013e31815c5f69.CrossRefPubMed
15.
go back to reference Brekken RA, Sage EH: SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 2000, 19: 569-580. 10.1016/S0945-053X(00)00105-0.CrossRefPubMed Brekken RA, Sage EH: SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 2000, 19: 569-580. 10.1016/S0945-053X(00)00105-0.CrossRefPubMed
16.
go back to reference Chua J, Seet LF, Jiang YZ, Su R, Htoon HM, Charlton A, Aung T, Wong TT: Increased SPARC expression in primary angle closure glaucoma iris. Mol Vis. 2008, 14: 1886-1892.PubMedPubMedCentral Chua J, Seet LF, Jiang YZ, Su R, Htoon HM, Charlton A, Aung T, Wong TT: Increased SPARC expression in primary angle closure glaucoma iris. Mol Vis. 2008, 14: 1886-1892.PubMedPubMedCentral
17.
go back to reference Seo JH, Park KH, Kim YJ, Yoo YC, Kang SH, Kim DM: Differences in the histopathology and matrix metalloproteinase expression in Tenon’s tissue of primary open-angle glaucoma and primary angle-closure glaucoma. Korean J Ophthalmol. 2008, 22 (1): 37-42. 10.3341/kjo.2008.22.1.37.CrossRefPubMedPubMedCentral Seo JH, Park KH, Kim YJ, Yoo YC, Kang SH, Kim DM: Differences in the histopathology and matrix metalloproteinase expression in Tenon’s tissue of primary open-angle glaucoma and primary angle-closure glaucoma. Korean J Ophthalmol. 2008, 22 (1): 37-42. 10.3341/kjo.2008.22.1.37.CrossRefPubMedPubMedCentral
18.
go back to reference Marchesi C, Dentali F, Nicolini E, Maresca AM, Tayebjee MH, Franz M, Guasti L, Venco A, Schiffrin EL, Lip GY, Grandi AM: Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens. 2012, 30 (1): 3-16. 10.1097/HJH.0b013e32834d249a.CrossRefPubMed Marchesi C, Dentali F, Nicolini E, Maresca AM, Tayebjee MH, Franz M, Guasti L, Venco A, Schiffrin EL, Lip GY, Grandi AM: Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens. 2012, 30 (1): 3-16. 10.1097/HJH.0b013e32834d249a.CrossRefPubMed
Metadata
Title
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in the aqueous humour of patients with primary angle closure glaucoma - a quantitative study
Authors
Angeline DC Nga
Soon-Lek Yap
Amir Samsudin
Puteri S Abdul-Rahman
Onn H Hashim
Zahari Mimiwati
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2014
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/1471-2415-14-33

Other articles of this Issue 1/2014

BMC Ophthalmology 1/2014 Go to the issue